Medium impact
Vedolizumab (Entyvio®)
BCBS Tennessee·Effective Dec 1, 2026
BlueCross BlueShield of Tennessee has issued a new medical policy for Vedolizumab (Entyvio®) effective December 1, 2026, establishing coverage criteria for four indications: moderately to severely active ulcerative colitis and Crohn's disease (12-month authorization), immune checkpoint inhibitor-related toxicity (6-month authorization), acute graft versus host disease (12-month authorization), and CAR T-cell-related toxicity (6-month authorization). The policy requires prior authorization, specific prescriber specialties, detailed documentation of clinical response for continuation, and prohibits concomitant use with other biologic or targeted synthetic drugs for the same indication.